Fulltext

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma

Schilling, B. ; Sondermann, W. ; Zhao, F. ; Griewank, K. G. ; Livingstone, E. ; Sucker, A. ; Zelba, H. ; Weide, B. ; Trefzer, U. ; Wilhelm, T. ; Loquai, C. ; Berking, C. ; Hassel, J. ; Kähler, K. C. ; Utikal, J. ; Al Ghazal, P. ; Gutzmer, R. ; Goldinger, S. M. ; Zimmer, L. ; Paschen, A. ; Hillen, U. ; Schadendorf, D.

In: Annals of Oncology, 2014, vol. 25, no. 3, p. 747-753

Ajouter à la liste personnelle
    Titre
    • Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
    Auteur
    • Schilling, B.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Sondermann, W.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Zhao, F.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Griewank, K. G.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Livingstone, E.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Sucker, A.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Zelba, H.. University Medical Center, University of Tübingen, Tübingen
    • Weide, B.. German Cancer Consortium (DKTK)
    • Trefzer, U.. German Cancer Consortium (DKTK)
    • Wilhelm, T.. German Cancer Consortium (DKTK)
    • Loquai, C.. German Cancer Consortium (DKTK)
    • Berking, C.. German Cancer Consortium (DKTK)
    • Hassel, J.. German Cancer Consortium (DKTK)
    • Kähler, K. C.. Department of Dermatology, Venerology and Allergology, University of Schleswig-Holstein Hospital, Campus Kiel
    • Utikal, J.. German Cancer Consortium (DKTK)
    • Al Ghazal, P.. Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
    • Gutzmer, R.. Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany
    • Goldinger, S. M.. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    • Zimmer, L.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Paschen, A.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Hillen, U.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    • Schadendorf, D.. Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2014, vol. 25, no. 3, p. 747-753. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300851
    Summary
    In this study, we demonstrate that vemurafenib but not dabrafenib reduces peripheral lymphocyte counts in melanoma patients while both agents show similar clinical efficacy. Within the lymphocyte compartment, vemurafenib selectively decreases circulating CD4+ T cells and changes their phenotype and function. This indicates that selective BRAFi need to be assessed individually for immunomodulatory effects, especially, when planning combinations with immunotherapies